Results from the daraxonrasib trial
The clinical trial included 61 patients with recently diagnosed advanced pancreatic cancer that had spread to other parts of the body. Tumours stopped growing in 90% of these patients. Over 60% of patients had tumours shrink or disappear, while for 8% of patients, tumours became undetectable on CT scans. In one in 12 patients, the cancer became undetectable. Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, said the results are "the closest to cure" because he saw so many tumours disappear in patients whose cancer had spread. He presented these findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Dr. Park said, "Just imagine, in an average of 18 months your disease just disappears on the CT scan, that’s closest to complete remission, it’s incredible." He noted that patients see deeper responses and a near doubling in the duration of disease control, which may translate into longer survival. During the median follow-up of 18 months, some patients did not see the cancer return.
Survival stats and mechanism of action
Patients receiving daraxonrasib had a 76.6% survival rate one year after starting treatment, while usually only 40-45% of patients given chemotherapy alone survive a year. This drug is a KRAS inhibitor that works by locking on to and shutting off certain mutations that drive tumour growth, though doctors say the pill cannot yet be considered a cure. Pancreatic cancer has the lowest survival rate of all common cancers in the UK, as half of all patients die within three months. Only about 3% of patients survive for five years when the disease spreads to other organs. Michelle Mitchell, the chief executive of Cancer Research UK, said this is the biggest leap forward seen in decades for pancreatic cancer patients and could offer real hope to those facing difficult diagnoses. She also stated that more trials are needed before the NHS assesses this treatment for use and noted that pancreatic cancer survival is still very low. Scientists hope the treatment could work for dozens of other cancers that carry similar Kras gene mutations.
